Eddy Anglade, M.D., has been appointed to the newly created position of executive vice president of Clinical Development at Advanced Cell Technology, Inc. Dr. Anglade is an experienced pharmaceutical executive with more than 16 years of experience overseeing clinical trials and regulatory affairs.
Dr. Anglade joins the company after co-founding Lux Pharmaceuticals and serving as its chief medical officer, where he guided the development of orphan designated and fast-track products as well as early phase development of a novel therapeutic agent for dry eye disease. He was responsible for recruitment and development of the clinical operations, program management, and medical writing teams, as well as the review of all studies. Previously he was vice president of Clinical Development at Enzon Pharmaceuticals, where he oversaw all clinical development activities and was a member of the R&D leadership team. He also served as a medical director for Hoffman-La Roche Inc.
“We created this new position as we prepare for our transition to Phase II of our AMD and SMD clinical trials. We are thrilled to welcome such an experienced and accomplished executive to our team at this critical point in the company’s evolution,” said Gary Rabin, chief executive officer of ACT. “Dr. Anglade has extensive experience in the development of therapeutics for treating diseases of the eye. He will make an excellent addition to the world-class management team at ACT as the company continues to work with its clinical development partners at many of the leading academic and scientific institutions in the world.”